Atef Mohammad Darwish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Atef Mohammad Darwish has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Ahmad F. Amin
2 shared publicationsMohammad H. Makarem
Department of Obstetrics and Gynecology, Assiut University Hospital, Assiut, Egypt
2 shared publicationsSuha M. Hamadeh
Department of Obstetrics and Gynecology, Assiut University Hospital, Assiut, Egypt
2 shared publicationsA.M. Ahmad
Department of Obstetrics and Gynecology, Assiut University Hospital, Assiut, Egypt
1 shared publicationA.M. Mohammad
Department of Obstetrics and Gynecology, Assiut University Hospital, Assiut, Egypt
1 shared publicationAhmad M. El-Sayed
Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt
1 shared publication
Latest Publications
- 30 November 2008
- Published by Elsevier in Fertility and Sterility
- Vol. 90 (5) , 1864-1868
Clinical efficacy of novel unidirectional buccoadhesive vs. vaginoadhesive bromocriptine mesylate discs for treating pathologic hyperprolactinemia
- 30 November 2008
- Published by Elsevier in Fertility and Sterility
- Vol. 90 (5) , 1864-1868
Clinical efficacy of novel unidirectional buccoadhesive vs. vaginoadhesive bromocriptine mesylate discs for treating pathologic hyperprolactinemia
- 31 December 2007
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 86 (12) , 1484-1489
Is there a role for hysteroscopic tubal occlusion of functionless hydrosalpinges prior to IVF/ICSI in modern practice?
Objectives. To determine whether hysteroscopic tubal occlusion will produce the same efficacy as laparoscopic tubal occlusion of functionless hydrosalpinx prior to IVF/ICSI. Design. A prospective comparative study. Setting. Endoscopy Unit of the Women's Health Center, Faculty of Medicine, Assiut University, Assiut, Egypt. Subjects. A pilot safety phase included 10 uteri removed by hysterectomy in perimenopausal women subjected to roller ball coagulation of the peritubal bulge. The study phase included 27 patients with uni‐ or bilateral functionless hydrosalpinges, who were randomly divided into 2 groups. Group A comprised 14 patients who were randomly allocated for laparoscopic occlusion. Group B included 13 patients scheduled for a hysteroscopic approach. Interventions. Laparoscopic occlusion of the isthmic part of the fallopian tube was carried out using bipolar diathermy in 9 (64%) cases or clips in 3 (21.4%) cases in Group A. Roller ball electrode of the resectoscope was utilised for occlusion of the tubal ostium under local, spinal, or general anesthesia in Group B. Second‐look office hysteroscopy was performed in Group B whenever possible. In both groups, hysterosalpingography or sonohysterography was carried out 1 month later to confirm tubal occlusion. Main outcome measures. Safety phase aimed at confirming tubal occlusion with minimal harm to adjacent tissues. Confirmed tubal occlusion of the functionless hydrosalpinx. Results. The safety phase resulted in bilateral complete occlusion of the proximal part of the tubes with secondary coagulation p = 0.0001) and hospital stay (2±1.8 versus 5±1.1h, p = 0.0001). Second‐look office hysteroscopy was performed in 8 cases in Group B and revealed no significant corneal lesions at the site of hysteroscopic occlusion. Conclusions. This preliminary study demonstrates the feasibility of hysteroscopic tubal occlusion of functionless hydrosalpinx in all cases with acceptable efficacy. It has the advantage of adding a valuable evaluation of the endometrial cavity prior to IVF/ICSI. It should be an option for treatment protocol in cases of functionless hydrosalpinges. Further large sample‐sized studies are required to test its impact on the implantation rate and clinical outcome.
- 31 December 2007
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 86 (12) , 1484-1489
Is there a role for hysteroscopic tubal occlusion of functionless hydrosalpinges prior to IVF/ICSI in modern practice?
Objectives. To determine whether hysteroscopic tubal occlusion will produce the same efficacy as laparoscopic tubal occlusion of functionless hydrosalpinx prior to IVF/ICSI. Design. A prospective comparative study. Setting. Endoscopy Unit of the Women's Health Center, Faculty of Medicine, Assiut University, Assiut, Egypt. Subjects. A pilot safety phase included 10 uteri removed by hysterectomy in perimenopausal women subjected to roller ball coagulation of the peritubal bulge. The study phase included 27 patients with uni‐ or bilateral functionless hydrosalpinges, who were randomly divided into 2 groups. Group A comprised 14 patients who were randomly allocated for laparoscopic occlusion. Group B included 13 patients scheduled for a hysteroscopic approach. Interventions. Laparoscopic occlusion of the isthmic part of the fallopian tube was carried out using bipolar diathermy in 9 (64%) cases or clips in 3 (21.4%) cases in Group A. Roller ball electrode of the resectoscope was utilised for occlusion of the tubal ostium under local, spinal, or general anesthesia in Group B. Second‐look office hysteroscopy was performed in Group B whenever possible. In both groups, hysterosalpingography or sonohysterography was carried out 1 month later to confirm tubal occlusion. Main outcome measures. Safety phase aimed at confirming tubal occlusion with minimal harm to adjacent tissues. Confirmed tubal occlusion of the functionless hydrosalpinx. Results. The safety phase resulted in bilateral complete occlusion of the proximal part of the tubes with secondary coagulation p = 0.0001) and hospital stay (2±1.8 versus 5±1.1h, p = 0.0001). Second‐look office hysteroscopy was performed in 8 cases in Group B and revealed no significant corneal lesions at the site of hysteroscopic occlusion. Conclusions. This preliminary study demonstrates the feasibility of hysteroscopic tubal occlusion of functionless hydrosalpinx in all cases with acceptable efficacy. It has the advantage of adding a valuable evaluation of the endometrial cavity prior to IVF/ICSI. It should be an option for treatment protocol in cases of functionless hydrosalpinges. Further large sample‐sized studies are required to test its impact on the implantation rate and clinical outcome.
- 12 November 2007
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 33 (6) , 781-787
Treatment options for bacterial vaginosis in patients at high risk of preterm labor and premature rupture of membranes
Aim: To estimate the efficacy of different therapeutic modalities on proven cases of bacterial vaginosis (BV) in patients at high risk of preterm labor and premature rupture of membranes. Methods: This was a longitudinal prospective comparative study set in the antenatal outpatient clinic of the department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt. Four hundred and sixty‐eight patients with a clinical picture of threatened preterm labor or at high risk of premature rupture of membranes in the third trimester were screened for BV. Positive BV was diagnosed in 156 patients. They were randomly classified into four equal groups according to the line of medical treatment. The treatments were: (i) oral metronidazole, (ii) clindamycin vaginal cream, (iii) oral clindamycin, or (iv) metronidazole vaginal suppositories. The effects of medical treatment on Amsel's criteria as well as maternal and fetal outcomes were measured. Results: Based on Amsel's criteria, 156 patients (33.3%) were diagnosed with BV. There was a significant disappearance of vaginal discharge, with decreased percentages of pH > 4.5, positive amine test, and clue cells after treatment of BV in the four groups without any statistically significant difference between them. There were variable effects of the different treatments on increasing birthweight values, admission to neonatal intensive care units, and prolongation of the gestational age. Some maternal adverse effects have been recorded. There were significant improvements of the outcomes for oral metronidazole and clindamycin compared with outcomes for intravaginal metronidazole and clindamycin. Conclusions: Metronidazole and clindamycin achieve nearly equivalent cure rates when administered orally or vaginally in patients at high risk of preterm labor and premature rupture of membranes. Oral metronidazole is considered the drug of choice in treating BV due its high cure rate, better outcomes, and low cost.
- 12 November 2007
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 33 (6) , 781-787
Treatment options for bacterial vaginosis in patients at high risk of preterm labor and premature rupture of membranes
Aim: To estimate the efficacy of different therapeutic modalities on proven cases of bacterial vaginosis (BV) in patients at high risk of preterm labor and premature rupture of membranes. Methods: This was a longitudinal prospective comparative study set in the antenatal outpatient clinic of the department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt. Four hundred and sixty‐eight patients with a clinical picture of threatened preterm labor or at high risk of premature rupture of membranes in the third trimester were screened for BV. Positive BV was diagnosed in 156 patients. They were randomly classified into four equal groups according to the line of medical treatment. The treatments were: (i) oral metronidazole, (ii) clindamycin vaginal cream, (iii) oral clindamycin, or (iv) metronidazole vaginal suppositories. The effects of medical treatment on Amsel's criteria as well as maternal and fetal outcomes were measured. Results: Based on Amsel's criteria, 156 patients (33.3%) were diagnosed with BV. There was a significant disappearance of vaginal discharge, with decreased percentages of pH > 4.5, positive amine test, and clue cells after treatment of BV in the four groups without any statistically significant difference between them. There were variable effects of the different treatments on increasing birthweight values, admission to neonatal intensive care units, and prolongation of the gestational age. Some maternal adverse effects have been recorded. There were significant improvements of the outcomes for oral metronidazole and clindamycin compared with outcomes for intravaginal metronidazole and clindamycin. Conclusions: Metronidazole and clindamycin achieve nearly equivalent cure rates when administered orally or vaginally in patients at high risk of preterm labor and premature rupture of membranes. Oral metronidazole is considered the drug of choice in treating BV due its high cure rate, better outcomes, and low cost.
- 1 November 2007
- Published by Elsevier in Fertility and Sterility
- Vol. 88 (5) , 1427-1430
A simplified novel laparoscopic formation of neovagina for cases of Mayer-Rokitansky-Küster-Hauser syndrome
- 1 November 2007
- Published by Elsevier in Fertility and Sterility
- Vol. 88 (5) , 1427-1430
A simplified novel laparoscopic formation of neovagina for cases of Mayer-Rokitansky-Küster-Hauser syndrome
- 1 April 2007
- Published by Springer Nature in Reproductive Sciences
- Vol. 14 (3) , 280-285
Superiority of Newly Developed Vaginal Suppositories Over Vaginal Use of Commercial Bromocriptine Tablets: A Randomized Controlled Clinical Trial
The objective of this study is to verify the safety and efficacy of new vaginal bioadhesive suppositories as compared with vaginal use of commercial bromocriptine tablets in hyperprolactinemic patients. This study is a randomized, double-blind, active comparator clinical trial in which a subset of patients had some pharmacokinetic measurements. The setting was an outpatient private infertility clinic in a developing country, and the subjects were 171 patients with hyperprolactinemia. A pilot phase comprised 32 patients who were divided into 2 groups. Group A comprised 16 patients who used vaginal suppositories containing 2.5 mg bromocriptine mesthylate with pluronics and bioadhesive agents once daily for 1 month, while group B included 16 patients who used commercial 2.5-mg bromocriptine mesthylate tablets inserted vaginally once daily for 1 month. The clinical phase comprised 139 patients who were again divided into 2 groups in the same way (group A, 68 patients; group B, 71 patients). Serum prolactin (SP) was measured before and after therapy in all cases. The main outcome measure was the decline of SP level after 1 month of therapy. In both groups, there was a significant decline of the SP. However, it was more significant in group A. Patient convenience was more evident, and local side effects were less in group A than group B in the clinical phase. The introduction of bioadhesive technology for bromocriptine mesylate/pluronic F-126 administration is valuable in achieving prominent serum prolactin reduction in hyperprolactinemic patients in a relatively short duration of therapy. The formulated vaginal suppositories expressed better convenience with minimal local side effects when compared with vaginally administered commercial bromocriptine tablets.
- 1 April 2007
- Published by Springer Nature in Reproductive Sciences
- Vol. 14 (3) , 280-285
Superiority of Newly Developed Vaginal Suppositories Over Vaginal Use of Commercial Bromocriptine Tablets: A Randomized Controlled Clinical Trial
The objective of this study is to verify the safety and efficacy of new vaginal bioadhesive suppositories as compared with vaginal use of commercial bromocriptine tablets in hyperprolactinemic patients. This study is a randomized, double-blind, active comparator clinical trial in which a subset of patients had some pharmacokinetic measurements. The setting was an outpatient private infertility clinic in a developing country, and the subjects were 171 patients with hyperprolactinemia. A pilot phase comprised 32 patients who were divided into 2 groups. Group A comprised 16 patients who used vaginal suppositories containing 2.5 mg bromocriptine mesthylate with pluronics and bioadhesive agents once daily for 1 month, while group B included 16 patients who used commercial 2.5-mg bromocriptine mesthylate tablets inserted vaginally once daily for 1 month. The clinical phase comprised 139 patients who were again divided into 2 groups in the same way (group A, 68 patients; group B, 71 patients). Serum prolactin (SP) was measured before and after therapy in all cases. The main outcome measure was the decline of SP level after 1 month of therapy. In both groups, there was a significant decline of the SP. However, it was more significant in group A. Patient convenience was more evident, and local side effects were less in group A than group B in the clinical phase. The introduction of bioadhesive technology for bromocriptine mesylate/pluronic F-126 administration is valuable in achieving prominent serum prolactin reduction in hyperprolactinemic patients in a relatively short duration of therapy. The formulated vaginal suppositories expressed better convenience with minimal local side effects when compared with vaginally administered commercial bromocriptine tablets.
- 5 October 2006
- Published by Springer Nature in Gynecological Surgery
- Vol. 4 (2) , 85-90
Fertility after laparoscopic management of gynecologic emergencies: the experience of a developing country
- 5 October 2006
- Published by Springer Nature in Gynecological Surgery
- Vol. 4 (2) , 85-90
Fertility after laparoscopic management of gynecologic emergencies: the experience of a developing country
- 1 April 2005
- Published by Elsevier in Fertility and Sterility
- Vol. 83 (4) , 1053-1055
Evaluation of a novel vaginal bromocriptine mesylate formulation: A pilot study
- 1 April 2005
- Published by Elsevier in Fertility and Sterility
- Vol. 83 (4) , 1053-1055
Evaluation of a novel vaginal bromocriptine mesylate formulation: A pilot study
- Open Access
- 1 January 2005
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 84 (5) , 483-485
Screening for bacterial vaginosis in high-risk pregnancy: the experience of a developing country
Click on the article title to read more.
- 1 January 2005
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 84 (5) , 483-485
Open AccessScreening for bacterial vaginosis in high-risk pregnancy: the experience of a developing country
Click on the article title to read more.
- Open Access
- 1 October 2004
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 19 (10) , 2391-2394
Cervical priming prior to operative hysteroscopy: a randomized comparison of laminaria versus misoprostol
BACKGROUND: We aimed to compare efficacy of intravaginal misoprostol versus endocervical laminaria tents prior to operative hysteroscopy in selected cases. METHODS: A total of 144 patients with diagnosed intrauterine lesions scheduled for operative hysteroscopy were randomly allocated to two groups according to method of cervical priming prior to the procedure. Misoprostol 200 μg was inserted into the posterior fornix of the vagina for patients in group A (n=72), while laminaria tents were inserted intracervically in group B patients (n=72). RESULTS: Both methods were effective for cervical dilatation with a mean cervical diameter of 7.5±1.2 and 7.6±1.2 mm respectively. There was no significant difference in the mean cervical diameter or the time required for cervical dilatation (51.6 versus 51.4 s respectively). In contrast, there was a significant difference between the groups with respect to the insertion difficulty and in doctors' and patients' assessments of the procedure. CONCLUSIONS: Both misoprostol and laminaria were equally effective in inducing proper cervical priming prior to operative hysteroscopy with minimal time of cervical dilatation. Nevertheless, misoprostol may be superior due to easy application, reduced cost, and patient convenience and acceptability.
- 1 October 2004
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 19 (10) , 2391-2394
Open AccessCervical priming prior to operative hysteroscopy: a randomized comparison of laminaria versus misoprostol
BACKGROUND: We aimed to compare efficacy of intravaginal misoprostol versus endocervical laminaria tents prior to operative hysteroscopy in selected cases. METHODS: A total of 144 patients with diagnosed intrauterine lesions scheduled for operative hysteroscopy were randomly allocated to two groups according to method of cervical priming prior to the procedure. Misoprostol 200 μg was inserted into the posterior fornix of the vagina for patients in group A (n=72), while laminaria tents were inserted intracervically in group B patients (n=72). RESULTS: Both methods were effective for cervical dilatation with a mean cervical diameter of 7.5±1.2 and 7.6±1.2 mm respectively. There was no significant difference in the mean cervical diameter or the time required for cervical dilatation (51.6 versus 51.4 s respectively). In contrast, there was a significant difference between the groups with respect to the insertion difficulty and in doctors' and patients' assessments of the procedure. CONCLUSIONS: Both misoprostol and laminaria were equally effective in inducing proper cervical priming prior to operative hysteroscopy with minimal time of cervical dilatation. Nevertheless, misoprostol may be superior due to easy application, reduced cost, and patient convenience and acceptability.
- 29 February 2004
- Published by Elsevier in Contraception
- Vol. 69 (2) , 121-127
Cervical changes associated with progestagen-only contraceptives: a team approach
- 29 February 2004
- Published by Elsevier in Contraception
- Vol. 69 (2) , 121-127
Cervical changes associated with progestagen-only contraceptives: a team approach